CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials

BACKGROUND: The cytochrome P450 (CYP) 2C9 enzyme plays a role in the metabolization of clopidogrel. Carriage of a CYP2C9 loss-of-function (LoF) allele has been associated with attenuated pharmacokinetics, leading to a diminished pharmacodynamic response and increased risk for developing stent thromb...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Broek, Wout W. A., Mani, Nabil, Azzahhafi, Jaouad, ten Berg, Jurriën M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006245/
https://www.ncbi.nlm.nih.gov/pubmed/36787094
http://dx.doi.org/10.1007/s40256-022-00565-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006245/
https://www.ncbi.nlm.nih.gov/pubmed/36787094
http://dx.doi.org/10.1007/s40256-022-00565-2

Ejemplares similares